We believe gene therapies have the potential to redefine medicine over the next decade.
However, the field has been constrained by technological and operational challenges that make it difficult and expensive to deliver new products. We have built a fully integrated engine that consolidates the critical infrastructure and technology needed to engineer, manufacture, characterize, and develop new gene therapies – and we are committed to systematically expanding the reach of this field to tackle some of the biggest problems in medicine.
KRIYA WAS FOUNDED TO ADDRESS THREE PRIMARY PROBLEMS LIMITING
THE GENE THERAPY FIELD
1. DISPARATE DATA SETS
While widespread efforts have been undertaken to identify and solve the molecular, immunological, and analytical challenges in gene therapy, these have been pursued by distinct organizations operating independently from one another. This has led to the proliferation of disconnected data silos, limiting progress in the field.
2. INCONSISTENT, UNSCALABLE MANUFACTURING
Historically, gene therapy manufacturing has relied on antiquated processes that are unreliable and unscalable. This has contributed to poor product quality and astronomically high costs that have impacted clinical performance and patient access.
3. NARROW THERAPEUTIC SCOPE
Product development in gene therapy has historically focused on a limited set of rare monogenic disorders. While tremendous clinical benefits have been achieved, gene therapy as a modality has the potential to impact a much broader universe of diseases.
INTRODUCING A FULLY INTEGRATED MODEL TO BREAK NEW GROUND IN GENE THERAPY
Kriya has established an ecosystem for delivering best-in-class technologies and therapeutics, with core business units in Technology, Manufacturing, R&D, and Therapeutics. Each business unit benefits from shared data and operational synergies to support rapid iterative improvements in design, development, and production.
